Colon cancer was also treated using UTMD technology with anti-PD-1, and the number and effector function of CD8+ T cells were systemically increased, thereby augmenting anti-PD-1 efficacy [118]. The gene discussed is PDCD1; the disease is malignant colon neoplasm.